Related references
Note: Only part of the references are listed.Varicella-Zoster Reactivation after Allogeneic Stem Cell Transplantation without Routine Prophylaxis—The Incidence Remains High
Ola Blennow et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Antiviral drug resistance in herpesviruses other than cytomegalovirus
Jocelyne Piret et al.
REVIEWS IN MEDICAL VIROLOGY (2014)
Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity
C. L. Vermont et al.
TRANSPLANT INFECTIOUS DISEASE (2014)
Persistence and Antiviral Resistance of Varicella Zoster Virus in Hematological Patients
Martha T. van der Beek et al.
CLINICAL INFECTIOUS DISEASES (2013)
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation
Ulrica Forslow et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients
Mats Remberger et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Resistance testing of clinical varicella-zoster virus strains
Andreas Sauerbrei et al.
ANTIVIRAL RESEARCH (2011)
A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT
A. Klein et al.
BONE MARROW TRANSPLANTATION (2011)
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
Marcie Tomblyn et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation
Veronique Erard et al.
BLOOD (2007)
Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study
M Boeckh et al.
BLOOD (2006)
The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation
KJ Thomson et al.
BONE MARROW TRANSPLANTATION (2005)
Increased antiviral activity of 1-O-hexadecyloxypropyl-[ 2-14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism
KA Aldern et al.
MOLECULAR PHARMACOLOGY (2003)
Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms
C Gilbert et al.
DRUG RESISTANCE UPDATES (2002)
Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome
E Saint-Léger et al.
CLINICAL INFECTIOUS DISEASES (2001)
Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome
Y Koc et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Varicella-zoster virus: Pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients
AM Arvin
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Share Paper
